Tad Eichler1,2, Kristin Bender1,2, Matthew J Murtha1,3, Laura Schwartz1,2, Jackie Metheny1, Lindsey Solden4, Robert M Jaggers4, Michael T Bailey3,4, Sudipti Gupta1,2, Claudia Mosquera1, Christina Ching1,2,3,5,6, Krista La Perle7, Birong Li1, Brian Becknell1,2,3,8,9, John David Spencer10,2,3,8,9. 1. Centers for Clinical and Translational Research and. 2. Nephrology and Urology Research Affinity Group. 3. Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio; and. 4. Microbial Pathogenesis, The Research Institute at Nationwide Children's, Columbus, Ohio. 5. Divisions of Urology and. 6. Departments of Pediatric Surgery and. 7. Comparative Pathology and Mouse Phenotyping Shared Resource, The Ohio State University College of Veterinary Medicine, Columbus, Ohio. 8. Nephrology, and. 9. Pediatrics, Nationwide Children's, Columbus, Ohio. 10. Centers for Clinical and Translational Research and John.Spencer@nationwidechildrens.org.
Abstract
BACKGROUND: Evidence suggests that antimicrobial peptides, components of the innate immune response, protect the kidneys and bladder from bacterial challenge. We previously identified ribonuclease 7 (RNase 7) as a human antimicrobial peptide that has bactericidal activity against uropathogenic Escherichia coli (UPEC). Functional studies assessing RNase 7's contributions to urinary tract defense are limited. METHODS: To investigate RNase 7's role in preventing urinary tract infection (UTI), we quantified urinary RNase 7 concentrations in 29 girls and adolescents with a UTI history and 29 healthy female human controls. To assess RNase 7's antimicrobial activity in vitro in human urothelial cells, we used siRNA to silence urothelial RNase 7 production and retroviral constructs to stably overexpress RNase 7; we then evaluated UPEC's ability to bind and invade these cells. For RNase 7 in vivo studies, we developed humanized RNase 7 transgenic mice, subjected them to experimental UTI, and enumerated UPEC burden in the urine, bladder, and kidneys. RESULTS: Compared with controls, study participants with a UTI history had 1.5-fold lower urinary RNase 7 concentrations. When RNase 7 was silenced in vitro, the percentage of UPEC binding or invading human urothelial cells increased; when cells overexpressed RNase 7, UPEC attachment and invasion decreased. In the transgenic mice, we detected RNase 7 expression in the kidney's intercalated cells and bladder urothelium. RNase 7 humanized mice exhibited marked protection from UPEC. CONCLUSIONS: These findings provide evidence that RNase 7 has a role in kidney and bladder host defense against UPEC and establish a foundation for investigating RNase 7 as a UTI prognostic marker or nonantibiotic-based therapy.
BACKGROUND: Evidence suggests that antimicrobial peptides, components of the innate immune response, protect the kidneys and bladder from bacterial challenge. We previously identified ribonuclease 7 (RNase 7) as a human antimicrobial peptide that has bactericidal activity against uropathogenic Escherichia coli (UPEC). Functional studies assessing RNase 7's contributions to urinary tract defense are limited. METHODS: To investigate RNase 7's role in preventing urinary tract infection (UTI), we quantified urinary RNase 7 concentrations in 29 girls and adolescents with a UTI history and 29 healthy female human controls. To assess RNase 7's antimicrobial activity in vitro in human urothelial cells, we used siRNA to silence urothelial RNase 7 production and retroviral constructs to stably overexpress RNase 7; we then evaluated UPEC's ability to bind and invade these cells. For RNase 7 in vivo studies, we developed humanized RNase 7 transgenic mice, subjected them to experimental UTI, and enumerated UPEC burden in the urine, bladder, and kidneys. RESULTS: Compared with controls, study participants with a UTI history had 1.5-fold lower urinary RNase 7 concentrations. When RNase 7 was silenced in vitro, the percentage of UPEC binding or invading human urothelial cells increased; when cells overexpressed RNase 7, UPEC attachment and invasion decreased. In the transgenic mice, we detected RNase 7 expression in the kidney's intercalated cells and bladder urothelium. RNase 7 humanized mice exhibited marked protection from UPEC. CONCLUSIONS: These findings provide evidence that RNase 7 has a role in kidney and bladder host defense against UPEC and establish a foundation for investigating RNase 7 as a UTI prognostic marker or nonantibiotic-based therapy.
Authors: Milan Chromek; Zuzana Slamová; Peter Bergman; László Kovács; L'udmila Podracká; Ingrid Ehrén; Tomas Hökfelt; Gudmundur H Gudmundsson; Richard L Gallo; Birgitta Agerberth; Annelie Brauner Journal: Nat Med Date: 2006-06-04 Impact factor: 53.440
Authors: Sheryl S Justice; Chia Hung; Julie A Theriot; Daniel A Fletcher; Gregory G Anderson; Matthew J Footer; Scott J Hultgren Journal: Proc Natl Acad Sci U S A Date: 2004-01-22 Impact factor: 11.205
Authors: M R Rossi; J R Masters; S Park; J H Todd; S H Garrett; M A Sens; S Somji; J Nath; D A Sens Journal: Environ Health Perspect Date: 2001-08 Impact factor: 9.031
Authors: Jorge J Canas; Dong Liang; Vijay Saxena; Jenaya Hooks; Samuel W Arregui; Hongyu Gao; Yunlong Liu; Danielle Kish; Sarah C Linn; Khalil Bdeir; Douglas B Cines; Robert L Fairchild; John D Spencer; Andrew L Schwaderer; David S Hains Journal: Proc Natl Acad Sci U S A Date: 2022-09-26 Impact factor: 12.779
Authors: Keith R Pierce; Tad Eichler; Claudia Mosquera Vasquez; Andrew L Schwaderer; Aaron Simoni; Steven Creacy; David S Hains; John D Spencer Journal: J Clin Invest Date: 2021-11-15 Impact factor: 19.456
Authors: Kristin Bender; Laura L Schwartz; Ariel Cohen; Claudia Mosquera Vasquez; Matthew J Murtha; Tad Eichler; Jason P Thomas; Ashley Jackson; John David Spencer Journal: Am J Physiol Renal Physiol Date: 2021-04-05
Authors: Elaise B Hill; Joshua R Watson; Daniel M Cohen; David Kline; Andrew L Schwaderer; John D Spencer Journal: Pediatr Nephrol Date: 2021-07-16 Impact factor: 3.714